Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over the counter (OTC) pharmaceutical business in Hong Kong and Mainland China.
FAIL · Does not pass the screen
0.10 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 13 days ago
Screened 2026-10-23 · the tape above runs as of 16:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price0.10 USD
Ethical score70.0/100
Our investment reviews on this name
2026-10-11Read Markdown0.12-16.7% to today ✓Distribution gives way to Markdown first Markdown read since September
2026-10-02Read Distribution0.12-16.7% to today ✓Markdown gives way to Distribution after a 68% slide in 4 weeks
2026-09-01Read Markdown0.38-73.7% to today ✓Distribution gives way to Markdown first Markdown read since July
2026-08-01Read Distribution0.38-73.7% to today ✓Markdown gives way to Distribution after an 8% slide in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Cellyan Biotechnology Co Ltd holds its Markdown at $0.10. Elevated stress, defensive posture warranted, held for 4 days.
As held on the ledger · 2026-10-23
Phase
Markdown · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 4 days
Price at the screen
$0.10
Valuation
N/A trailing · N/A forward price to earnings
Values screen
FAIL· score 70.0
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
25.22%
Below 33%
Interest-bearing debt is just 25.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
23.96%
Below 33%
Cash held in interest-bearing accounts and securities is 24.0% of assets, under the one-third limit.
Pass
Receivables
57.39%
Below 49%
Money owed to the company is 57.4% of assets, above the 49% limit.
Fail
Revenue purity
0.01%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Cellyan Biotechnology's business is fine, but its receivables are about 57% of its assets, just over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when HKPD's ethical verdict changes
Today HKPD does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Hong Kong and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
HKPD trades on NASDAQ (the company is based in Hong Kong). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-26Markdown$0.10-12.6%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 12.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 79%. Our forward projection puts the odds of a 10% gain over the next month near 21%.
2026-10-11Markdown · changed$0.12+0.0%Entry 7
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 79%. Our forward projection puts the odds of a 10% gain over the next month near 21%.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 68.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 79%. Our forward projection puts the odds of a 10% gain over the next month near 21%.
2026-09-01Markdown · changed$0.38+0.0%Entry 5
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 79%. Our forward projection puts the odds of a 10% gain over the next month near 21%.
2026-08-01Distribution · changed$0.38-8.4%Entry 4
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 8.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 79%. Our forward projection puts the odds of a 10% gain over the next month near 21%.
2026-07-18Markdown$0.42+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 79%. Our forward projection puts the odds of a 10% gain over the next month near 21%.
2026-07-03Markdown$0.42+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markdown$0.42Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.